Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial
Condition studied
Congenital hemophilia A (HA), Synovitis
Investigational medicinal product(s)
Every trial of Efanesoctocog alfa across our registers →
Eligibility
Primary endpoint
Proportion of patients with treatment response (TR) after 12 months. TR is defined as a reduction or resolution of synovial hypertrophy in at least one affected joint according to the synovial hypertrophy domain of the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score performed by blinded ultrasound expert (BLUE) team
Endpoint detail
related to pharmacokinetics and efficacy for bleed prevention of ERT: ■ FVIII trough level ■ Time spent at FVIII activity >30 IU/dL ■ Time spent at FVIII activity >50 IU/dL ■ Annualized bleeding rate (ABR, all treated bleeds) and annualized joint bleeding rate (AjBR, treated joint bleeds only), related to assessments and clinical relevance of synovitis: ■ Proportion of joints with TR ■ Proportion of patients with complete resolution of synovitis in all of their joints, related to safety of efanesoctocog alfa: ■ Treatment-emergent adverse events (TEAE)
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-523896-44-00 on CTIS ↗ ← All trials in the EU